about
Current State of Animal (Mouse) Modeling in Melanoma ResearchRealizing the clinical potential of cancer nanotechnology by minimizing toxicologic and targeted delivery concernsAcid ceramidase is upregulated in AML and represents a novel therapeutic target.Identification of glycogen synthase kinase 3α as a therapeutic target in melanomaMacrophage inhibitory cytokine-1 regulates melanoma vascular developmentTransiently entrapped circulating tumor cells interact with neutrophils to facilitate lung metastasis developmentRobust activation of the human but not mouse telomerase gene during the induction of pluripotency.Leelamine mediates cancer cell death through inhibition of intracellular cholesterol transport.Targeting multiple key signaling pathways in melanoma using leelamine.Nanolipolee-007, a novel nanoparticle-based drug containing leelamine for the treatment of melanoma.eEF-2 kinase dictates cross-talk between autophagy and apoptosis induced by Akt Inhibition, thereby modulating cytotoxicity of novel Akt inhibitor MK-2206.Improving pharmacological targeting of AKT in melanoma.Nanoparticle-Based Celecoxib and Plumbagin for the Synergistic Treatment of Melanoma.Synergistic inhibitory effects of Celecoxib and Plumbagin on melanoma tumor growth.Targeting V600EB-Raf and Akt3 using nanoliposomal-small interfering RNA inhibits cutaneous melanocytic lesion development.Models of melanoma metastasis: using a transient siRNA-based protein inhibition strategy in mice to validate the functional relevance of pharmacological agents.Systemic delivery of liposomal short-chain ceramide limits solid tumor growth in murine models of breast adenocarcinoma.Synthesis and characterization of a novel iNOS/Akt inhibitor Se,Se'-1,4-phenylenebis(1,2-ethanediyl)bisisoselenourea (PBISe)--against colon cancer.Akt3 and mutant V600E B-Raf cooperate to promote early melanoma development.Identification of WEE1 as a target to make AKT inhibition more effective in melanoma.Propagation of Undifferentiated Human Embryonic Stem Cells with Nano-Liposomal CeramideDownregulation of CD73 associates with T cell exhaustion in AML patientsLoss of PTEN promotes tumor development in malignant melanomaMethod of mutation analysis may contribute to discrepancies in reports of (V599E)BRAF mutation frequencies in melanocytic neoplasmsSchweinfurthin natural products induce regression of murine melanoma and pair with anti-PD-1 therapy to facilitate durable tumor immunityThe novel Isatin analog KS99 targets stemness markers in acute myeloid leukemiaOptimizing live-animal bioluminescence imaging prediction of tumor burden in human prostate cancer xenograft models in SCID-NSG mice
P50
Q26781652-3ED0E028-E249-4903-B71D-7AC33C708E7CQ28396462-8C7CB1CF-8E0E-4881-8B35-5E4900DC342DQ30275460-56BAC596-6BB5-404A-A7B5-50A73A4985FBQ33569998-619A1A2C-0238-4343-BD99-44B91546154EQ33882542-E790648D-477F-4B2B-9B11-7E661241494CQ34001179-4453CEB2-EB21-4195-8DDB-B0BD60D0C560Q34017109-761A7663-564E-461A-8D2A-26FE6A684859Q34413011-7EEF40CD-B076-457C-9704-24AE5C57183FQ35136450-B138C945-E7F5-4680-ACEF-6181E6DB3F49Q35225907-A2BCDBD7-E319-4584-8BE1-7BB7F768A974Q35534450-6AC38C80-E48B-40B5-B9A6-98FB400F54D0Q38680192-F7016F64-D461-4B57-9246-C2CD40972B25Q38724921-174BC4D9-E39A-46E6-A1F0-0E58B66F516FQ38738291-DFF51960-4342-44D6-A873-5FAF178387FBQ39899988-0FDCA45F-96D2-432B-A729-C53274BD1BA0Q40087403-60CA550A-C2FF-410E-BB25-2767C1950663Q40427915-03764DDE-172A-4E97-A653-D9E1E2AC9AB6Q41493952-C5B93284-66CB-425D-84EE-E8C45A89F40CQ41859138-80CDE4AB-2F33-43B9-8096-44D5D61421E7Q48155250-BDF8DDF4-054F-4BCC-8C9D-A3E3899D4AB5Q61992564-20749E98-59E1-462B-9938-07305B243E25Q64094669-74099B7B-114E-4994-A122-AA7423A41145Q73469277-E3C04CA2-00F1-4514-859D-147CFEA902BEQ80857390-5DF3B08F-5360-4D9B-A9C6-34356FC1BB59Q91324168-61A56642-5A43-429B-8D80-FE83DDF197ACQ92253982-10F9D10E-F839-417E-824F-3A446E3622F7Q92929380-00AECE5B-80DB-4D6D-AFFF-29935E1DC2E2
P50
description
researcher
@en
wetenschapper
@nl
հետազոտող
@hy
name
Arati Sharma
@ast
Arati Sharma
@en
Arati Sharma
@es
Arati Sharma
@nl
type
label
Arati Sharma
@ast
Arati Sharma
@en
Arati Sharma
@es
Arati Sharma
@nl
prefLabel
Arati Sharma
@ast
Arati Sharma
@en
Arati Sharma
@es
Arati Sharma
@nl
P106
P31
P496
0000-0001-7178-949X